drugset / Trial / NCT00646776

Drug Interaction Study

NCT00646776

Phase 1 Completed 85 enrolled Bristol-Myers Squibb
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the exposure of rifabutin (RIB) when administered with atazanavir and ritonavir (ATV/RTV)

Timeline

Start
2008-04
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atazanavir Other / unclassified 300 mg Oral
Comparator Rifabutin Small molecule 150 mg Oral
Comparator Ritonavir Other / unclassified 100 mg Oral

Indications

No indication recorded.